Aktienanalyse zu Geron Corp (GERN)GERNGeron Corp

Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Geron Corp (GERN) appears to be a good buy right now due to its recent revenue growth of 17.05% over the last 20 days, and a gross margin of 94.94% in Q2 2026, indicating strong profitability potential despite current losses. The main risk is the net loss of $16.7 million in Q2 2026, which could affect investor sentiment if it persists.

3 analysts cover GERN: 1 rate it Buy, 2 Hold and 0 Sell. The average price target is 4.00.